Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask: About Monteverde & Associates PC NEW YORK, Jan. 5, 2026 /PRNewswire/ --Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Clas ...

Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and strategic buyouts.-- ARS Pharma's neffy, an emergency treatment for allergic reactions, received regulatory approval in China, while Vanda's NEREUS secured in the United States. -- FONAR Corp., the inventor of MR Scanning, is set to be taken private by its CEO-LED group. -- New analyses from InflaRx's halted phase 3 Vilobelimab trial h ...

The U.S. stock market is closing out 2025 on a cautious note, with futures for major indexes edging lower on Wednesday, December 31st, extending a three-session losing streak. Hopes for a traditional year-end "Santa Claus" rally appear to be fading, as investors grapple with mixed economic signals and a divided outlook from the Federal Reserve for the upcoming year. Despite the recent pullback, 2025 has been a remarkable year for equities, with the S&P 500 (SPX) poised for its third consecutive year of doub ...

Core Viewpoint - Ademi LLP is investigating FONAR for potential breaches of fiduciary duty and legal violations related to a recent transaction involving management and board members [1] Group 1: Transaction Details - FONAR stockholders will receive $19.00 per share for common stock, $6.34 per share for Class C common stock, and $10.50 per share for Class A non-voting preferred stock [3] - The transaction includes significant benefits for FONAR insiders as part of change of control arrangements [3] Group 2: Investigation Focus - The transaction agreement imposes a significant penalty on FONAR for accepting competing bids, which may limit shareholder options [4] - The investigation will assess whether the FONAR board is fulfilling its fiduciary duties to all shareholders [4]

Market Sentiment - The CNN Money Fear and Greed index showed a decline in overall market sentiment, remaining in the "Neutral" zone with a reading of 48.9, down from 49.1 [4] - U.S. stocks settled lower, with the Dow Jones index falling 0.2% and the S&P 500 recording losses for the third consecutive session [1][3] Economic Data - The Case-Shiller Home Price Index increased by 1.3% year-over-year in October, slightly lower than the previous month's 1.4% surge but above market estimates of 1.1% [2] - The FHFA house price index rose by 0.4% in October, rebounding from a 0.1% decline in September and exceeding market expectations of a 0.1% increase [2] - The Chicago Business Barometer surged to 43.5 in December from 36.3 in the previous month, surpassing market expectations of 39.5 [2] Sector Performance - Most sectors on the S&P 500 closed negatively, with consumer discretionary, industrials, and financials experiencing the largest losses [3] - Energy and communication services sectors closed higher, contrasting with the overall market trend [3]

Core Viewpoint - The proposed sale of FONAR Corporation to affiliates of CEO Timothy Damadian and certain executives and directors is under investigation to assess whether the offered consideration adequately reflects the company's value [1]. Summary by Relevant Sections - **Proposed Transaction Details** - Shareholders of FONAR will receive $19.00 per share for common stock, $19.00 per share for Class B common stock, and $6.34 per share for Class C common stock [1]. - **Investigation Purpose** - Kahn Swick & Foti, LLC is investigating the adequacy of the proposed sale consideration and the process leading to this valuation to determine if it undervalues the company [1].

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Tuesday.The Dow traded down 0.22% to 48,353.51 while the NASDAQ slipped 0.16% to 23,436.70. The S&P 500 also fell, dropping, 0.13% to 6,896.56.Check This Out: AAR Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate AnalystsLeading and Lagging SectorsEnergy shares rose by 0.6% on Tuesday.In trading on Tuesday, consumer discretionary stocks fell by 0.3%.Top Headlin ...

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the sale of FONAR Corporation to its CEO and certain executives, focusing on whether the transaction terms are equitable for shareholders [1][3]. Group 1: Transaction Details - FONAR's Class B common stock is being sold for $19.00 per share, while Class C common stock is priced at $6.34 per share [1]. - The investigation aims to determine if the sale price reflects the best possible consideration for shareholders [3]. Group 2: Legal Concerns - The investigation questions whether FONAR and its board violated federal securities laws and fiduciary duties by not ensuring the best price for shareholders [3]. - There are concerns about whether the buyers are underpaying for FONAR and if all material information necessary for shareholders to assess the merger has been disclosed [3]. Group 3: Potential Actions - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other forms of relief related to the proposed transaction [4].

U.S. stock futures swung between gains and losses on Tuesday after Monday’s declines. Futures of major benchmark indices were mixed.The Santa Claus rally, which began on Dec. 24 last week, seems to have resumed gains after a day of losses on Monday.Meanwhile, President Donald Trump escalated his long-standing conflict with Federal Reserve Chair Jerome Powell on Monday by threatening a lawsuit over alleged “gross incompetence,” a move that has reignited concerns regarding central bank independence just month ...

Group 1 - TEN Holdings Inc. announced a $2.25 million private placement of 991,000 shares at $2.27 per share, resulting in a 17% increase in shares to $1.65 in after-hours trading [1] - Fonar Corp. shares surged 24% to $18.18 after announcing a definitive agreement for a "take private" sale [1] - CapsoVision Inc. submitted its 510(k) application to the FDA for its AI-assisted module for CapsoCam Plus, leading to an 11% decline in shares to $11.58 [1] - Verastem Inc. intends to discontinue the RAMP 203 clinical study in advanced KRAS G12C-mutated non-small cell lung cancer, causing shares to fall 2.7% to $7.55 [1] - Dermata Therapeutics Inc. closed a $12.4 million private placement priced at-the-market under Nasdaq rules, with shares jumping 10.2% to $2.05 in after-hours trading [1]